Change Country
Welcome to LuxembourgWelcome
Please read the important information below before continuing to our website

The Lyxor ETFs on this website may be restricted for certain individuals or in certain countries pursuant to the national regulations applicable to those individuals or countries. It is therefore your responsibility to ensure that you are authorised to invest in the Lyxor ETFs on this website. 


If you are an investor in the United Kingdom, please go to  

If you are an investor in the Netherlands, please go to  

If you are an investor in Italy, please go to  

If you are an investor in Spain, please go to  

If you are an investor in Austria, please go to  

If you are an investor in Germany, please go to   

If you are an investor in Singapore, please go to  

If you are an investor in Switzerland, please go to  

If you are an investor in Belgium, please go to  

If you are an investor in Poland, please go to 

If you are an investor in Norway, please go to

If you are an investor in Denmark, please go to

If you are an investor in Luxembourg, please go to

If you are an investor in Sweden, please go to

If you are an investor in Finland, please go to



The Lyxor ETFs on this website are undertakings for collective investment in transferable securities (UCITS) (i) domiciled in France and approved by the Autorité des Marchés Financiers (AMF) or, (ii) domiciled in Luxembourg, approved by the Commission de Surveillance du Secteur Financier (CSSF) and authorised to market their units or shares in the French Republic in accordance with the notification procedure under Article 93 of Directive 2009/65/EC. Investors should note that the prospectuses of certain Lyxor ETFs under Luxembourg law that have been notified in accordance with this procedure are only available on the website in English. A French translation of these prospectuses can be obtained upon request by sending a letter to Lyxor International Asset Management (“Lyxor”) – 17 Cours Valmy, 92987 Paris La Défense, France.


The information on this website is not intended for persons or entities that are resident, located or registered in jurisdictions that are not authorised to distribute Lyxor ETFs. As a result, the information on this website does not constitute an offer or solicitation to buy or sell units or shares in these ETFs by anyone in any jurisdiction:


(a)   in which such an offer or solicitation is unauthorised;

(b)   in which Lyxor is not qualified to make such an offer or solicitation; or 

(c)   in which it is unlawful to make such an offer or solicitation.


In particular, the Lyxor ETFs on this website are not and will not be registered under the United States Securities Act of 1933, as amended. As such, they may not be offered or sold within the United States of America, except in specific cases where transactions are exempt from registration under the Securities Act. The ETFs listed on this website may not be sold to US citizens or transferred to the United States by any other means, unless this transaction is not subject to any specific registration under US law. 


Any person from a jurisdiction to which the above-mentioned restrictions apply should inform themselves of and observe these restrictions.


This website is intended for commercial purposes and is not regulatory in nature. Although the information provided has been drawn up on the basis of sources considered to be reliable, there is no guarantee that it is accurate, complete or relevant. Some of the information on this website is provided on the basis of market data collected at a specific time and may therefore vary over time. Lyxor advises investors to read the risk factors section of the prospectus and the key investor information document carefully. These documents can be found on the website.


The net asset value (“NAV”) of Lyxor ETFs may at any time be subject to considerable price fluctuations, which in some cases may lead to the loss of all of the capital invested. Investors should note that some ETFs may be sensitive to fluctuations in the exchange rate between their reference currency and that of the underlying index, as well as of the components of the underlying index.


Before investing in a Lyxor ETF, you should carry out your own risk analysis of the product from a legal, tax and accounting perspective, rather than basing your decision solely on the information provided. If necessary, you should consult your own advisers or any other qualified professional. 


Subject to compliance with the legal obligations by which they are bound, Lyxor or any entity within the same group shall not be held liable for any financial or other consequences of an investment in the product. 



By clicking on institutional or individual above, I confirm that I have read and understood the information provided herein, and that I am resident or registered in Luxembourg.


30 Sep 2019

Five ways to position your equity portfolio into year-end

We’re entering the final quarter of 2019 after a bumpy summer of trade disputes and recession fears. How should investors position equity portfolios to see out the year?  

Bond and equity market valuations are sending conflicting signals. The bond market has $16.1trn of negative-yielding debt, which has pushed investors into riskier assets. This looks inconsistent with typical allocation at such an advanced stage of the economic cycle. Either the bond market is overly pessimistic, or equities are too positive. If it’s the latter, any readjustment would likely be painful. Ultimately, a slowdown in activity or mild recession is to be expected after more than a decade of growth.

Looking ahead, political uncertainty will remain a wild card and sentiment will likely be a drag on global equities, particularly as central banks have little room for manoeuvre on rates policy. Selectivity and asset quality will remain key to maintain performance in equity portfolios in the quarter ahead.

With all that in mind, here we share five ways to position your equity portfolio into year-end.  

1. US equities: Likely to stay resilient

We expect US economic growth to bottom out over the next quarter, which should help the Fed anchor market expectations on its future policy actions. The Fed’s current policy on rates is aligned with mid-cycle monetary policy adjustments. More than 75bps of rate cut would be interpreted as policy reaction to counter a recession phase.

The US remains our preferred equity market due to the US economy’s domestic focus. The US stock market also tends to be less volatile than other global regions. The US is a more closed economy and has more headroom for policy support.

We believe the Fed will cut again at the December meeting. Any move by President Trump to offer the US consumer some relief from the US/China trade war would also support the market. New tariffs on Chinese goods in the months ahead could add another 0.2-0.3% to inflation in the short-term. 

2. European equities: Caution advised 

There are three main reasons to be careful on European equities, despite recent signs of stabilisation: lingering risks linked to Brexit, vulnerable consumer confidence and economic growth, and the risk of another escalation of trade tensions, with the potential for US tariffs on European luxury goods.  

In our view, easing financial conditions and fiscal support may not be enough to offset the lack of earnings growth and the slowdown in global trade. We have preference for high quality stocks and volatility reduction strategies. Small caps should also be more sensitive to any deterioration in activity, so we favour large caps.    

3. European sectors: Load up on defensives

With low earnings prospects and heightened geopolitical risks, we maintain our preference for defensive sectors.

We like sectors exhibiting strong balance sheets and better earnings growth potential such as Healthcare, Consumer Staples and Utilities. These sectors would prove more resilient in a slowdown in economic activity. We keep a neutral stance on Financials as, despite its attractive valuations, the sector suffers low rates and weak profitability prospects. While the ECB’s new tiering system on banks deposit will provide some relief, the outlook for banks is more driven by long-term bond yields and the outlook for economic growth.  

Defensive sectors outperform when the economic environment deteriorates

                         Chart 1

Source: Lyxor International Asset Management, Macrobond, data as at 30/08/2019

4. EM equities: Cheaply priced, but be selective

Valuation in emerging markets (EM) equities are attractive compared to developed markets, with the former’s price to book value trading at 35% discount (see chart below). However, the developing world will remain very sensitive to trade war developments and economic growth prospects in China. The tariffs war exacerbates the downside in the Chinese Yuan and spreads to other Asian currencies. This weigh on growth of China’s trading partners too – see our Trade War Impact Indicator for a reminder of the most vulnerable countries. Overall, we expect greater dispersion in returns among EM countries.  A trade truce would offer greater respite to the most affected. We also believe that an allocation to Chinese equities should be managed independently of a broader emerging equities portfolio.  

Emerging markets at discount relative to Developed market equities

chart 2

Source: Lyxor international Asset Management, Refintiv, MSCI, data as at 31/08/2019

5. Indian equities: More upside expected  

India is one of the few bright spots within the developing world. The local equity market relies on internal growth engines and is less dependent on exports than China. While the country still faces many challenges, the government’s latest move to reduce corporate taxes is a bold measure to revive growth. The test in coming months will be to see whether corporates share some of the profitability boost into the economy via greater investment or price cuts on products to stimulate demand. In our view, ongoing policy initiatives and a dovish central bank should provide further upside to Indian equities in a context of attractive valuations. 

Risk Warning

This document is for the exclusive use of investors acting on their own account and categorised either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2014/65/EU. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on, and upon request to

Except for the United-Kingdom, where this communication is issued in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658, this communication is issued by Lyxor International Asset Management (LIAM), a French management company authorized by the Autorité des marchés financiers and placed under the regulations of the UCITS (2014/91/EU) and AIFM (2011/61/EU) Directives. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Research disclaimer

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures and disclaimers. Alternatively, visit our global research disclosure website

Conflicts of interest 

This research contains the views, opinions and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on linkedin